Related Experiment Video
Updated: Nov 22, 2025

A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
Cardiac Involvement in Eosinophilic Granulomatosis With Polyangiitis: A Retrospective Study in the Chinese Population
Yingying Chen1, Xiaoxiao Guo2, Jiaxin Zhou1
1Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Ministry of Health, Beijing, China.
Insights
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) affects younger patients with higher eosinophil counts and disease activity. Early cardiac screening and treatment are crucial for improving outcomes in these patients.
Area of Science:
- Rheumatology
- Cardiology
- Internal Medicine
Background:
- Cardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) is linked to poor prognosis and high mortality.
- Limited data exists on cardiac involvement in EGPA within the Chinese population.
Purpose of the Study:
- To investigate the clinical characteristics and outcomes of Chinese EGPA patients with cardiac involvement.
- To identify factors associated with cardiac involvement in EGPA.
Main Methods:
- Retrospective analysis of clinical data from 83 EGPA patients.
- Comparison of clinical features between EGPA patients with and without cardiac involvement.
Main Results:
- Prevalence of cardiac involvement in this EGPA cohort was 27.7%.
- Patients with cardiac involvement were younger at onset, had higher eosinophil counts, and higher disease activity (BVAS).
- Cardiac involvement was associated with a poorer prognosis (FFS ≥ 1), though outcomes improved with treatment, with low mortality.
Conclusions:
- Cardiac involvement in EGPA is associated with younger age, elevated eosinophils, increased disease activity, and worse prognosis.
- Comprehensive cardiac evaluation and timely treatment are vital for improving survival and outcomes in EGPA patients with cardiac manifestations.
Abstract:
Introduction: Cardiac involvement in eosinophilic granulomatosis with polyangiitis (EGPA) is associated with a poor prognosis and high mortality; however, few studies about cardiac involvement in EGPA in the Chinese population are available. We conducted this study to determine the clinical characteristics and overall outcomes of Chinese EGPA patients with cardiac involvement. Materials and Methods: We retrospectively collected the clinical data of 83 patients diagnosed with EGPA and analyzed the differences between the patients with and without cardiac involvement. Results: The prevalence of cardiac involvement in EGPA in this cohort was 27.7%. Compared with those without cardiac involvement, EGPA patients with cardiac involvement tended to have a younger age at onset (mean ± SD: 38.4 ± 10.5 vs. 42.1 ± 15.9 years, respectively, p = 0.039), higher eosinophil count (median [IQR]: 5810 [4020-11090] vs. 2880 [1530-6570] n/μL, respectively, p = 0.004), higher disease activity assessed using the Birmingham vasculitis activity score (BVAS) (median [IQR]: 20 [16-28] vs. 15 [12-18], respectively, p = 0.001), and poorer prognosis (Five Factor Score [FFS] ≥ 1: 100% vs. 38.3%, respectively, p = 0.001). In the cardiac involvement group, 43.5% of patients were asymptomatic, but cardiac abnormalities could be detected by cardiac examinations. With appropriate treatment, the overall outcomes of EGPA patients with cardiac involvement in our cohort were good, with only 3 (13.0%) patients dying in the acute phase and no patients dying during follow-up. Conclusions: Cardiac involvement in EGPA was associated with a younger age at onset, higher eosinophil count, higher disease activity, and a poorer prognosis. Comprehensive cardiac examinations and appropriate treatment are essential to improve the prognosis of those with cardiac involvement.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Cardiomyopathy III: Hypertrophic Cardiomyopathy

